Bayer claims Abbott’s Humira infringes its patent
Bayer filed suit against Abbott Dec. 24 alleging that Humira (adalimumab) infringes its patent covering a composition of human monoclonal antibodies which bind to human tumor necrosis factor alpha. Bayer said the patent, No. 5,654,407, which was issued in 1997, does not cover a specific Bayer drug. Humira, a blockbuster autoimmune therapy, had worldwide sales of $3.1 billion in 2007 and is projected to generate $4.4 billion in sales for 2008 (1"The Pink Sheet," Oct. 20, 2008, p. 5). The complaint, filed in the U.S. District Court for the Eastern District of Texas, requests a jury trial and a finding of willful infringement. Abbott said Humira does not infringe Bayer's patent and that it believes the patent is invalid
You may also be interested in...
Sales of Abbott's multi-faceted biologic Humira seem to be going from strength to strength, unencumbered by the economic turmoil even though it's an expensive biologic in highly competitive markets
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”